Tu Van Dao

2.8k citations
36 papers · 539 · 1 hit paper · h-index 10

Impact in

  • Hepatology top 5%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers

Papers in

Tu Van Dao

31 papers receiving 532 citations

Tu Van Dao's Hit Papers

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. 2022 · 259 citations
2590+1+2Years since publication50100150200250

Peers

Tu Van Dao
Comparison fields: 5 of 58
  • Hepatology 206
  • Oncology 238
  • Cancer Research 73
  • Pulmonary and Respiratory Medicine 134
  • Pathology and Forensic Medicine 72
Replace Abdul Siddique with:
Abdul Siddique United Kingdom
Chunlin Jiang China
Jan J. J. de Vries Netherlands
Jinfen Wang China
Daniel Karl United States
Zhiyuan Cai China
Kai Lei China
Zihao Dai China
Linjing An China
Tu Van Dao relative to Abdul Siddique United Kingdom Abdul Siddique's profile →
Citations per field
00.5×1.5×2.3×
Abdul Siddique · 1×
Citations per year

Countries citing papers authored by Tu Van Dao

Since Specialization
Citations

This map shows the geographic impact of Tu Van Dao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tu Van Dao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tu Van Dao more than expected).

Fields of papers citing papers by Tu Van Dao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tu Van Dao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tu Van Dao. The network helps show where Tu Van Dao may publish in the future.

Co-authors

The 25 scholars most cited alongside Tu Van Dao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tu Van Dao Line = papers co-authored together Tu Van Dao links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Hit paper breakdown →
2022259
2 202272
3 202232
4 201727
5 201921
6 202217
7 201715
8 202014
9 201811
10 202010
11 20249
12 20206
13 20176
14 20195
15
[Cancer of the gallbladder. Epidemiology, diagnosis and prognostic factors].
19935
16 20214
17 20214
18 20223
19 20193
20 20222

About Tu Van Dao

Tu Van Dao is a scholar working on Oncology, Electrical and Electronic Engineering, Control and Systems Engineering, Pulmonary and Respiratory Medicine and Surgery, having authored 36 papers that have together received 539 indexed citations. Recurring topics across this work include Microgrid Control and Optimization (8 papers), Smart Grid Energy Management (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Renal cell carcinoma treatment (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Hepatology (206 citations), Oncology (238 citations), Cancer Research (73 citations), Pulmonary and Respiratory Medicine (134 citations) and Pathology and Forensic Medicine (72 citations). Tu Van Dao has collaborated with scholars based in Vietnam, Japan and United States. Frequent co-authors include Yasuhiro Hayashi, Hideo Ishii, Bruno Sangro, Lorenza Rimassa, George Lau, В. В. Бредер, Philip He, Vincent C. Tam, Wattana Sukeepaisarnjaroen and Kabir Mody. Their work appears in journals such as Cancer Control, Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology and International Journal of Electrical Power & Energy Systems.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact